心导管室是否仍需保留裸金属支架?
本文回顾裸金属支架(BMS)相较普通球囊扩张的进步及其再狭窄问题,指出药物洗脱支架需延长双联抗血小板治疗且存在晚期支架血栓风险,而新一代药物洗脱支架安全性和有效性改善、可缩短双联抗血小板治疗时长;作者据此论述心导管室仍需保留BMS的理由。
要点
- BMS较普通球囊扩张是冠心病介入治疗的重要进步。
- BMS靶病变血运重建率高,促成药物洗脱支架发展。
- 新一代药物洗脱支架安全有效且可缩短双联抗血小板疗程。
核心结论
- 作者论述心导管室仍需保留裸金属支架(BMS)。
研究设计与样本
- 本文为综述,未报告检索范围与纳入样本量。
主要发现
- BMS靶病变血运重建率高,药物洗脱支架需延长双联抗血小板治疗且晚期及极晚期支架血栓风险增加。
- 新一代药物洗脱支架较早期一代及BMS安全性和有效性更好,允许更短的双联抗血小板治疗时长。
临床怎么用
- 心导管室应保留BMS作为可选器械。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The introduction of bare-metal stents (BMS) has represented a major advancement over plain old balloon angioplasty in the management of coronary artery disease. However, the high rates of target lesion revascularization associated with use of BMS have led to the development of drug-eluting stents, which require prolonged dual antiplatelet therapy due to the increased risk of late and very late stent thrombosis. The improvements in newer-generation drug-eluting stents have translated into better safety and efficacy compared with earlier generation and BMS, thus allowing shorter dual antiplatelet therapy duration. Here, we aim to provide reasons as to why we still need BMS in our cardiac catheterization laboratory.
引用
- Colombo A, Giannini F, Briguori C, et al. Should We Still Have Bare-Metal Stents Available in Our Catheterization Laboratory? J Am Coll Cardiol. 2017. PMID: 28750704. doi:10.1016/j.jacc.2017.05.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。